Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Debt to Equity (2016 - 2025)

IGC Pharma (IGC) has disclosed Debt to Equity for 15 consecutive years, with $0.02 as the latest value for Q3 2025.

  • On a quarterly basis, Debt to Equity fell 10.86% to $0.02 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.02, a 10.86% decrease, with the full-year FY2025 number at $0.02, up 13.12% from a year prior.
  • Debt to Equity was $0.02 for Q3 2025 at IGC Pharma, down from $0.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.02 in Q2 2025 to a low of $0.0 in Q2 2021.
  • A 5-year average of $0.01 and a median of $0.01 in 2023 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 838.42% in 2021; the steepest drop was 81.41% in 2021.
  • IGC Pharma's Debt to Equity stood at $0.01 in 2021, then surged by 53.31% to $0.01 in 2022, then surged by 98.03% to $0.02 in 2023, then skyrocketed by 40.45% to $0.02 in 2024, then dropped by 23.81% to $0.02 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Debt to Equity are $0.02 (Q3 2025), $0.02 (Q2 2025), and $0.02 (Q1 2025).